HC Wainwright reissued their neutral rating on shares of Kodiak Sciences (NASDAQ:KOD - Free Report) in a research report released on Friday,Benzinga reports. They currently have a $3.00 price target on the stock.
Kodiak Sciences Trading Up 4.3 %
Shares of NASDAQ:KOD traded up $0.23 during trading on Friday, hitting $5.53. 596,695 shares of the stock were exchanged, compared to its average volume of 478,590. The company has a fifty day moving average price of $3.29 and a two-hundred day moving average price of $3.03. The company has a market cap of $290.96 million, a PE ratio of -1.43 and a beta of 2.26. Kodiak Sciences has a 12-month low of $1.89 and a 12-month high of $7.77.
Kodiak Sciences (NASDAQ:KOD - Get Free Report) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.86) EPS for the quarter, topping analysts' consensus estimates of ($0.87) by $0.01. Equities research analysts anticipate that Kodiak Sciences will post -3.52 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Kodiak Sciences
Several institutional investors and hedge funds have recently bought and sold shares of KOD. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Kodiak Sciences during the first quarter valued at approximately $68,000. Sei Investments Co. acquired a new stake in shares of Kodiak Sciences during the 1st quarter valued at $595,000. Headlands Technologies LLC acquired a new stake in shares of Kodiak Sciences during the 1st quarter valued at $50,000. State Board of Administration of Florida Retirement System acquired a new stake in shares of Kodiak Sciences during the 1st quarter valued at $86,000. Finally, Vanguard Group Inc. raised its holdings in shares of Kodiak Sciences by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 1,654,448 shares of the company's stock valued at $8,702,000 after purchasing an additional 10,978 shares in the last quarter. Institutional investors and hedge funds own 89.06% of the company's stock.
About Kodiak Sciences
(
Get Free Report)
Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.
Recommended Stories
Before you consider Kodiak Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kodiak Sciences wasn't on the list.
While Kodiak Sciences currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
